Drugs / AdimrSC-2f
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04522089 | Aug → Nov 2020 | COVID-19 | Adimmune Corporation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05104489 | Jan → Dec 2022 | COVID-19 | Adimmune Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdimrSC-2f | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05104489 ↗ |
| Modality | Vaccine | “AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune).” NCT04522089 ↗ |
| Route | Intramuscular | “0.5 mL intramuscular (IM) injection” NCT05104489 ↗ |